Nestlé Health Science has announced that it has reached a non-binding memorandum of understanding with Seres Therapeutics for the acquisition of specific assets related to Vowst. This agreement will replace any previous agreements between Nestlé and Seres concerning Vowst.
Vowst, an orally administered microbiota-based therapeutic, has been authorized by the FDA for preventing recurrence of Clostridioides difficile infection in adults following antibiotics for recurrent CDI. It is not intended for treating CDI itself. Nestlé Health Science, which has been the primary commercialization partner for Vowst since its launch in June 2023 in the United States, will gain full control over the continued development, commercialization, and production of Vowst once the transaction is finalized.
The announcement was made by Moreno Perugini, president of medical nutrition and pharma at Nestlé Health Science. “We have seen great success with Vowst since its introduction to patients last year,” he said. “Our collaboration with Seres during the development and FDA approval process was fruitful, and we are excited to continue providing this essential medication to patients.”
Perugini also noted that Nestlé Health Science’s portfolio focuses on nutritional science while its pharma business specializes in medical conditions related to gastrointestinal disorders. Vowst fits within our expertise and addresses a significant unmet need in the market. He believes that sales will continue to increase, benefiting many more patients. The completion of the transaction is subject to the negotiation of definitive agreements, approval from Seres shareholders, and other standard conditions.
